REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in September:
Cantor Global Healthcare Conference
Presentation Date: Wednesday, September 3, 2025 at 1:00 PM ET
Presentation Format: Fireside Chat
Webcast: Here
Wells Fargo Healthcare Conference
Presentation Date: Thursday, September 4, 2025 at 1:30 PM ET
Presentation Format: Fireside Chat
Webcast: Here
H.C. Wainwright 27th Annual Global Investment Conference
Presentation Date: Monday, September 8, 2025 at 4:00 PM ET
Presentation Format: Fireside Chat
Baird Global Healthcare Conference
Presentation Date: Tuesday, September 9, 2025 at 2:00 PM ET
Presentation Format: Fireside Chat
Bernstein 2nd Annual Healthcare Forum
Presentation Date: Thursday, September 25, 2025 at 9:40 AM ET
Presentation Format: Fireside Chat
Replays of the Cantor and Wells Fargo events will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The Company’s first commercial product, VYKAT™ XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
| Last Trade: | US$67.67 |
| Daily Change: | -0.74 -1.08 |
| Daily Volume: | 737,229 |
| Market Cap: | US$3.600B |
August 06, 2025 July 10, 2025 July 01, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
